Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About DMD
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About DMD
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay

Ravindranath Reddy Gilibili, Sagnik Chatterjee, Pravin Bagul, Kathleen W. Mosure, Bokka Venkata Murali, T. Thanga Mariappan, Sandhya Mandlekar and Yurong Lai
Drug Metabolism and Disposition June 2017, 45 (6) 604-611; DOI: https://doi.org/10.1124/dmd.116.074740
Ravindranath Reddy Gilibili
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagnik Chatterjee
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pravin Bagul
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen W. Mosure
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bokka Venkata Murali
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Thanga Mariappan
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandhya Mandlekar
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yurong Lai
Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 45 no. 6 604-611
DOI 
https://doi.org/10.1124/dmd.116.074740
PubMed 
28325716

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received December 21, 2016
  • Accepted March 17, 2017
  • Published online April 27, 2017.

Article Versions

  • Earlier version (March 21, 2017 - 07:25).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ravindranath Reddy Gilibili,
  2. Sagnik Chatterjee,
  3. Pravin Bagul,
  4. Kathleen W. Mosure,
  5. Bokka Venkata Murali,
  6. T. Thanga Mariappan,
  7. Sandhya Mandlekar, and
  8. Yurong Lai1
  1. Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore, India (R.R.G., S.C., P.B., B.V.M., T.T.M.); Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, New Jersey (K.W.M., Y.L.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India (S.M.)
  1. Address correspondence to:
    Sagnik Chatterjee, Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Center (BBRC), Syngene International Ltd., Bangalore 560100, India. E-mail: sagnik.chatterjee{at}syngeneintl.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: March 2017 to April 2018

AbstractFullPdf
Mar 2017120716251
Apr 201750320159
May 20172787559
Jun 20171154059
Jul 2017782331
Aug 201758721
Sep 2017741828
Oct 20175667
Nov 201745920
Dec 20174678
Jan 2018671619
Feb 2018381215
Mar 2018381216
Apr 2018381818

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 45 (6)
Drug Metabolism and Disposition
Vol. 45, Issue 6
1 Jun 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
Citation Tools
Research ArticleArticle

Coproporphyrin-I as Novel In Vitro Probe Substrate for MRP2

Ravindranath Reddy Gilibili, Sagnik Chatterjee, Pravin Bagul, Kathleen W. Mosure, Bokka Venkata Murali, T. Thanga Mariappan, Sandhya Mandlekar and Yurong Lai
Drug Metabolism and Disposition June 1, 2017, 45 (6) 604-611; DOI: https://doi.org/10.1124/dmd.116.074740

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Coproporphyrin-I as Novel In Vitro Probe Substrate for MRP2

Ravindranath Reddy Gilibili, Sagnik Chatterjee, Pravin Bagul, Kathleen W. Mosure, Bokka Venkata Murali, T. Thanga Mariappan, Sandhya Mandlekar and Yurong Lai
Drug Metabolism and Disposition June 1, 2017, 45 (6) 604-611; DOI: https://doi.org/10.1124/dmd.116.074740
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolism of a 5HT6 antagonist, 2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole (SAM-760): impact of sulfonamide metabolism on diminution of a ketoconazole mediated clinical drug-drug interaction
  • Abundance of Phase I and II Drug Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study
  • Structure-activity relationships of the main bioactive constituents of Euodia ruticarpa on aryl hydrocarbon receptor activation and bile acid homeostasis
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2018 by the American Society for Pharmacology and Experimental Therapeutics